Introduction {#s001}
============

*Aspergillus species* are the most common ubiquitous spore-bearing fungal pathogens. *A. fumigatus* is one of the leading causative agents of invasive aspergillosis and acute bronchopulmonary aspergillosis.^[@B1]^ *A. fumigatus* causes infection in the form of invasive aspergillosis in the allogeneic hematopoietic stem cell transplant, HIV patients and individuals having cancer. *A. fumigatus* causes allergy in asthmatic or cystic fibrosis patients.^[@B2],[@B3]^ Allergy results from hypersensitive reaction to *Aspergillus* allergens in patients with atopic asthma or having cystic fibrosis disease.^[@B2]^ Diseases associated with *A. fumigatus* allergens are increasing compared with other fungal allergens and, furthermore, it adds problems to life-threatening infections in immunocompromised patients such as patients having cancer, HIV, and those who have undergone organ transplants.^[@B2],[@B4]^ Globally, it has been estimated that of 193 million asthmatic patients, 4,837,000 have allergic bronchopulmonary aspergillosis (ABPA).^[@B5]^ Recent data suggested that the fungal-associated allergic reactions or infections are increasing worldwide.^[@B1]^ To control *Aspergillus*-associated problems, various studies have been conducted for the development of a vaccine candidate against aspergillosis that showed promising results in mouse models.^[@B6]^ However, the use of recombinant allergens (*Asp f3* and *Asp f2*) or crude extract and homology to host protein showed certain limitations.^[@B6],[@B7],[@B9]^ Furthermore, the emergence of drug resistance isolate of *A. fumigatus* opens up new challenges for *A. fumigatus*-associated infections.^[@B10]^ Over the last few decades, the use of azole fungicides increased in agriculture that led to emergence of azole-resistant *A. fumigatus* strain.^[@B11]^ Other major hurdles in fungal vaccine designing are the pathogenesis process, evading of pathogen from the immune system, host genetic factors such as highly polymorphic nature of major histocompatibility complex (MHC) genes present in the population, and genetic variation in pathogen recognition receptors (PRRs).^[@B12],[@B13]^ Polymorphisms in PRRs (TLR, Pentraxins, etc.) can modulate host response against the microbes and that needs to be addressed for better immune response against the vaccines.^[@B14],[@B15]^ Till now, there is no vaccine or allergen shot therapy for *Aspergillus*-induced allergies.^[@B16]^ In a recent development, epitopic peptide-based approaches to map potential vaccine candidates have gained importance.^[@B17]^ Designing of vaccine against *A. fumigatus* possibly needs integration of the immunoinformatics or immunogenetic approach.^[@B12]^

Thus, to map the epitopic region from the reported allergens of *A. fumigatus*, we used different *in silico* approaches to predict potential human and mouse MHC class I and MHC class II T cell or B cell epitopic region from protein sequence of *A. fumigatus\'*s allergens. Mouse MHC class II and MHC class I T cell epitopes were predicted because common epitopes that recognize both human and mouse MHC T cell epitopes might be tested on model organism for their therapeutic potential and their results can be tested on human subjects.^[@B18]^ Another purpose for screening of epitopic peptides of antigens from *A. fumigatus* with no homologs in humans is that they recognize both MHC class I and MHC class T cells of human. Other than vaccine or allergy shot candidate, such peptides can be directly used *ex vivo* for the development of *A. fumigatus*-specific T cells (Asp-STs) for adoptive immunotherapy of invasive aspergillosis in the allogeneic hematopoietic stem cell transplant individuals having hematopoietic malignancies.^[@B4]^ With the advancement of technology or various omics approaches, they pave the way to discover novel therapeutic or drug targets for both communicable and noncommunicable diseases that have serious impact in both developed or developing countries.^[@B19]^ In this study, we used the reverse vaccinology approach that resulted in identification of potential peptides or allergen shot candidate against *A. fumigatus*-induced infections or allergies.

Materials and Methods {#s002}
=====================

Retrieval of *A. fumigatus* allergens {#s003}
-------------------------------------

*A. fumigatus* allergens known to date were retrieved from [www.allergen.org](www.allergen.org), which provided the allergen data sets classified by WHO/IUIS/allergen nomenclature subcommittee, an international organization that is responsible for maintaining and developing a unique, unambiguous, and systematic nomenclature for allergenic proteins.

Protein sequence retrieval {#s004}
--------------------------

The complete amino acid sequences of allergenic proteins were retrieved from [www.allergen.org](www.allergen.org) and National Center for Biotechnology Information database (NCBI) ([www.ncbi.nlm.nih.gov](www.ncbi.nlm.nih.gov)). A total of 23 allergens of *A. fumigatus* were retrieved from NCBI database and further explored for vaccine or allergen shot candidates for *A. fumigatus*-induced infections.

Identification of protein sequence similarity with the host {#s005}
-----------------------------------------------------------

Sequence similarity of the allergenic protein with host\'s protein sequences, for example, *Homo sapiens* (Taxid: 9606) and model organism *Mus musculus* (Taxid: 10090), was carried out using the basic local alignment search tool (BLASTp). The hit with an expectation value (E-value) less than 10^−4^ was excluded from the analysis and these protein sequences were assumed to have high sequence similarity with the host and model organism\'s proteome.^[@B18]^

Antigenicity prediction of allergens {#s006}
------------------------------------

Antigenicity of allergenic proteins was predicted by the use of VaxiJen v2.0 server, which provides the antigenic profile of bacterial, viral, parasitic, and fungal proteins. We choose the threshold value of 0.4 to increase the accurate antigenicity and to avoid false-positive results.^[@B19]^

Mapping of B cell epitope {#s007}
-------------------------

Each allergen protein sequence was then subjected to B cell epitope prediction using immune epitope database analysis resource (IEDB-AR). It is a linear B cell epitope prediction software that uses a different method to predict the linear B cell epitope. In this software, we use the BepiPred method for the prediction of B cell epitope. BepiPred program uses a combination of hidden Markov and propensity scale methods to find out the linear B cell epitope in antigenic proteins.^[@B20],[@B21]^

Mapping of T cell epitope {#s008}
-------------------------

### (1) T cell MHC class I epitope mapping {#s009}

T cell MHC class I-restricted epitopes from the set of allergenic proteins were identified using IEDB-AR programs available at the IEDB-AR.^[@B21]^ This database contains data sets of experimentally characterized B cell and T cell epitopes for humans and other model organisms that are used for vaccine research (mouse and nonhuman primates). MHC class molecules bind with antigens and then these bound antigens or epitopes are recognized by T cells for further processing. Inhibitory concentration (IC50) values were calculated for peptide epitopes that bind to MHC alleles, and on the bases of IC value, T cell epitopes were classified as follows: low-affinity IC50 value \<5000 nM, intermediate-affinity IC50 value \<500 nM, and high-affinity IC50 value \<50 nM. We considered only lower IC50 value epitopes because lower value indicates higher binding affinity of epitopes with host MHC alleles. We used all mouse MHC class I alleles (H-2-Db, H-2-Dd, H-2-Kb, H-2-Kd, H-2-Kk, and H-2-Ld)^[@B18]^ and eight human MHC class I alleles that cover about 85--90% of the world population (A\*0101, A\*0201, A\*2402, A\*0301, A\*1101, B\*0702, B\*0801, and B\*1501). The epitopes for T cell MHC class I alleles were identified by submitting the FASTA format of allergenic protein sequence to IEDB-AR. The artificial neural network (ANN) method was used to predict nine-mer sequence MHC class I epitopes.^[@B18]^

### (II) Mapping of T cell MHC class II epitope {#s010}

T cell MHC class II-restricted epitopes were identified using IEDB-AR.^[@B21]^ We used mouse MHC class II alleles and most common human MHC class II molecule DR alleles. The epitopes for T cell MHC class II alleles were identified by submitting the FASTA format of allergenic protein sequence to IEDB-AR. The 15-mer sequence epitope identification was performed using the consensus method.^[@B22]^ This method uses combination of stabilized matrix alignment and average relative binding matrix strategies to deduce MHC class II epitopes. This approach showed the best performance and is highly sensitive among other similar methods.^[@B18]^

Sequence identity mapping of epitopes with host proteome {#s011}
--------------------------------------------------------

The most common predicted B cell and T cell epitopic regions of allergenic proteins were further subjected for sequence similarity with protein sequences of human or mouse to eliminate any possible autoimmune response in the host. BLASTp program was used to predict the similarity.^[@B23]^

3D structure modeling and characterization of epitopes {#s012}
------------------------------------------------------

Using 10 allergenic proteins, *Asp f1*, *Asp f2*, *Asp f5*, *Asp f17*, and *Asp f34* allergenic proteins containing both T cell and B cell epitopes (in mouse and human) were subjected to 3D structure modeling for epitopic region characterization. The FASTA formats of these proteins were subjected to Phyre2 server to make the 3D structure of target allergenic protein.^[@B24]^ BLAST of protein sequences using Phyre2 server against the protein data bank (PDB) was performed and few best hits based on the structural alignment were used as template. Out of five allergens, the PDB template was predicted for only *Asp f1* and *Asp f5* allergenic proteins. For the best template, predicted PDB files were subjected to ModRefiner for refinement of structure.^[@B25]^ Energy minimization of these structures was carried out by YASARA force field minimization tool that improves overall quality of predicted protein structures.^[@B26]^ Furthermore, modeled structures were validated by RAMPAGE ([http://mordred.bioc.cam.ac.uk/∼rapper/rampage.php](http://mordred.bioc.cam.ac.uk/∼rapper/rampage.php)), a program that has been extensively used for stereochemical characteristics of predicted structures of the protein. PyMOL program ([www.pymol.org/](www.pymol.org/)) was used to illustrate the predicted structures of epitopes. The position of predicted epitopes was also visualized by PyMOL.

Result and Discussion {#s013}
=====================

Allergic disorders such as asthma, atopic dermatitis, and allergic rhinitis caused by *A*. *fumigatus* have gained public attention. *A. fumigatus* not only causes ABPA but also is responsible for allergic *Aspergillus* sinusitis, hypersensitivity pneumonitis, and IgE-mediated asthma.^[@B27]^ Various strategies have been used to treat allergies such as allergen avoidance and elimination, subcutaneous injection of allergenic extract, and allergen shots.^[@B28]^ Immunotherapy involves the subcutaneous administration of gradually increasing quantities of allergens or allergen epitopic peptides until a dose has been reached that is effective enough to induce immunologic tolerance to these allergens. The goal of allergen-specific immunotherapy (SIT) is to subside the symptoms induced by allergens and further to reduce the recurrence of disease in the long term.^[@B29]^ In a recent report, it is observed that allergic incidence was caused by *Alternaria alternata* where whole crude antigens were used as SIT.^[@B30],[@B31]^ So, attention has been focused on envisaging peptides that display both MHC class I and, especially, MHC class II T cell epitopes.^[@B32]^ A multitope vaccine or allergen shots having epitopes from several allergens may provide protection from *A. fumigatus* infections or allergies. In this direction, the reverse vaccinology approach has been employed to discover best epitopic peptides from *A. fumigatus* for experimental prioritization for vaccine or allergen shot candidates. The overall strategy used in this work is given in [Figure 1](#f1){ref-type="fig"}.

![Overall strategy used for prediction of vaccine or allergy shot candidates against *Aspergillus*-induced infections and allergy.](fig-1){#f1}

A total of 23 allergens of *A. fumigatus* were derived from allergen database and are presented in [Table 1](#T1){ref-type="table"}. These retrieved allergenic proteins of *A. fumigatus* were used to predict a vaccine or allergic shot candidate and have also been analyzed for ideal epitopic regions. Initially, these 23 allergenic proteins were subjected to homology search with host and mouse (model organism) proteome. A similar epitopic region, if selected for vaccine or allergy shots against *A. fumigatus*, may lead to devastating cross-reaction in host or it might lead to autoimmune diseases.^[@B33],[@B34]^ Thus, it is important to screen the best allergenic protein that can be considered as potential vaccine or allergic shot candidate for experimental studies. Therefore, to obtain similarity between allergenic proteins and host or model organisms proteome, BLASTp was performed against mouse and human proteins. Of 23 allergenic proteins of *A. fumigatus*, 13 allergic proteins (*Asp f3, Asp f6, Asp f8, Asp f10, Asp f11, Asp f12, Asp f13, Asp f18, Asp f22, Asp f23, Asp f27, Asp f28,* and *Asp f29)* showed high sequence similarity with host and model organism. Thus, these allergenic proteins were eliminated from further analysis due to their role in potential cross-reactivity. Remaining 10 allergenic proteins (*Asp f1, Asp f2, Asp f4, Asp f5, Asp f7, Asp f9, Asp f15, Asp f16, Asp f17,* and *Asp f 34)* ([Table 2](#T2){ref-type="table"}) were considered for antigenicity analysis. All 10 allergenic proteins predicted to be most probable antigens by VaxiJen server having a threshold value \>0.4. The antigenicity score of each of these allergens is given in [Table 2](#T2){ref-type="table"}. Furthermore, these allergens were subjected to map B and T cell epitopes.

###### 

**Allergen Retrieved from [www.allergen.org](www.allergen.org)**

  *Aspergillus fumigatus*               
  ------------------------- ----------- ------
  *Asp f1*                  166486      18
  *Asp f2*                  1881574     37
  *Asp f3*                  2769700     19
  *Asp f4*                  3005839     30
  *Asp f5*                  3776613     40
  *Asp f6*                  1648970     26.5
  *Asp f7*                  2879888     12
  *Asp f8*                  6686524     11
  *Asp f9*                  2879890     34
  *Asp f10*                 963013      34
  *Asp f11*                 5019414     24
  *Asp f12*                 1930153     90
  *Asp f13*                 2295        34
  *Asp f15*                 3005841     16
  *Asp f16*                 3643813     43
  *Asp f17*                 2980819      
  *Asp f18*                 2143220     34
  *Asp f22*                 13925873    46
  *Asp f23*                 21215170    44
  *Asp f27*                 91680605    18
  *Asp f28*                 91680607    13
  *Asp f29*                 91680609    13
  *Asp f34*                 133920236   20

###### 

**Antigenicity of Allergen**

  Antigen     GI number   Protein name             Antigenicity score (Threshold \>0.4)
  ----------- ----------- ------------------------ --------------------------------------
  *Asp f1*    166486      Mitogillin               0.7540
  *Asp f2*    1881574     Hypothetical protein     0.8795
  *Asp f4*    3005839     Hypothetical protein     1.0311
  *Asp f5*    3776613     Metalloprotease          0.5683
  *Asp f7*    2879888     Hypothetical protein     0.8011
  *Asp f9*    2879890     Hypothetical protein     0.7615
  *Asp f15*   3005841     Hypothetical protein     0.8088
  *Asp f16*   3643813     Hypothetical protein     0.9120
  *Asp f17*   2980819     IgE-binding protein      0.9860
  *Asp f34*   133920236   Cell wall protein PhiA   0.5564

B and T cell epitope mapping {#s014}
----------------------------

*In silico* tools become important for selecting good epitopic regions from immunodominant proteins that can save the screening time or expenses of synthetic peptides.^[@B13],[@B19]^ It has been established that T and B lymphocytes act as antigenic determinants or epitopes of antigens instead of entire antigens. T cell recognizes epitopic peptides using T cell receptor that binds to either MHC I (CD8^+^ T cell) or MHC II (CD4^+^ T cells) class molecules or both present on antigen-presenting cells. Furthermore, T helper (CD4^+^ T cells) cells induce the B cells to activate humoral immune response.^[@B18]^ Ten antigenic allergenic proteins of *A. fumigatus* were subjected for mapping of linear B cell epitopes using the IEDB-AR BepiPred method. The identification of B cell epitopes is important for vaccine design, diagnosis, and antibody production.^[@B35],[@B36]^ B cell epitopes are antigenic determinants that are recognized by the paratope region of membrane-bound antibodies or receptors on B-lymphocytes.^[@B18]^ All the identified B cell epitopes are listed in [Table 3](#T3){ref-type="table"}. Previously, it has been observed that allergen epitopes mainly comprised hydrophobic amino acids, and amino acids, Ser, Gly, Ala, and particularly Lys, play an important role in IgE antibody binding allergenic epitopic peptides.^[@B37],[@B38]^ Our results showed very few lysine residues in predicted epitopic peptides from *Asp f1*, *Asp f2*, *Asp f5*, *Asp f17*, and *Asp f34* allergens ([Table 4](#T4){ref-type="table"}).

###### 

**Linear B Cell Epitopes for Allergen**

  Serial No.   Allergen    GI number   Start   End   Epitope
  ------------ ----------- ----------- ------- ----- ---------------------------------------------------------------------
  **1**        *Asp f1*    166486      1       24    MVAIKNLFLLAATAVSVLAAPSPL
                                       35      48    QQLNPKTNKWEDKR
                                       104     118   RPPKHSQNGMGKDDH
                                       132     142   YKFDSKKPKED
                                       81      97    GYDGNGKLIKGRTPIKF
  **2**        *Asp f2*    1881574     20      37    TLPTSPVPIAARATPHEP
                                       56      63    CNATQRRQ
                                       97      105   GNRPTMEAV
                                       124     133   DNPDGNCALE
                                       136     146   GGHWRGANATS
                                       169     179   YTVAGSETNTF
                                       215     225   SNGTESTHDSE
                                       242     304   PGVGCAGESHGPDQGHDTGSASAPASTSTSSSSSGSGSGATTTPTDSPSATIDVPSNCHTHEG
  **3**        *Asp f4*    3005839     21      44    EWSGEAKTSDAPVSQATPVSNAVA
                                       46      97    AAAASTPEPSSSHSDSSSSSGVSADWTNTPAEGEYCTDGFGGRTEPSGSGIF
                                       101     108   NVGKPWGS
                                       111     120   IEVSPENAKK
                                       128     135   VGSDTDPW
                                       143     153   IGPDGGLTGWY
                                       169     195   YVAFDENSQGAWGAAKGDELPKDQFGG
                                       221     228   IQAENAHH
                                       264     275   VDGIGGKVVPGP
  **4**        *Asp f5*    3776613     51      69    TVIEAPSSFAPFKPQSYVE
                                       119     127   NVGKDGKVF
                                       132     144   SFYTGQIPSSAAL
                                       147     158   RDFSDPVTALKG
                                       170     182   DSASSESTEEKES
                                       255     274   INDPTEGERTVIKDPWDSVA
                                       280     318   ISDGSTNYTTSRGNNGIAQSNPSGGPSYLNNYRPSSSSL
                                       324     335   YSVSSSPPSSYI
                                       360     376   EKAGNFEYNTNGQGGLG
                                       385     405   QDGSGTNNANFATPPDGQPGR
                                       471     510   LKPGDKRSTDYTMGEWASNRAGGIRQYPYSTSLSTNPLTY
                                       541     559   HGKNDAPKPTLRDGVPTDG
  **5**        *Asp f7*    2879888     1       15    SSGYSGPCSKGSPCV
                                       21      41    YDTATSASAPSSCGLTNDGFS
  **6**        *Asp f9*    2879890     31      58    TWSKCNPLEKTCPPNKGLAASTYTADFT
                                       68      94    VTAGKVPVGPQGAEFTVAKQGDAPTID
                                       110     116   AAPGTGV
                                       196     207   YNDAKGGTRFPQ
                                       217     231   WAGGDPSNPKGTIEW
                                       233     243   GGLTDYSAGPY
                                       252     270   IENANPAESYTYSDNSGSW
  **7**        *Asp f15*   3005841     18      32    LAAPTPENEARDAIP
                                       34      55    SVSYDPRYDNAGTSMNDVSCSN
                                       73      91    FARIGGAPTIPGWNSPNCG
                                       109     117   DAAPGGFN
                                       138     150   ATYEEADPSHCAS
  **8**        *Asp f16*   3643813     27      40    PLAETCPPNKGLAA
                                       58      84    VTAGKVPVGPQGAEFTVAKQGDAPTID
                                       127     160   GDTTQVQTNYFGKGDTTTYDRGTYVPVATPQETF
                                       186     197   YNDAKGGTRFPQ
                                       207     218   GPAATPATPGHH
                                       271     337   SSSSSVTSSTTSTASSASSTSSKTPSTSTLATSTKATPTPSGTSSGSNSSSSAEPTTTGGSGSSNTG
                                       351     378   STGSSTSAGASATPELSQGAAGSIKGSV
                                       391     399   CWHSKQNDD
  **9**        *Asp f17*   2980819     3       11    LVSREAPAV
                                       29      42    SSYNGGDPSAVKSA
                                       51      65    NSGVDTVKSGPALST
                                       98      106   AANAGGTVY
                                       111     118   AQYTAADS
                                       125     133   AKVPESLSD
  **10**       *Asp f34*   133920236   13      26    AATASAAACQAPTN
                                       39      48    AVQYQPFSAA
                                       58      71    SQNASCDRPDEKSA
                                       75      92    IQDGSLYLYAASATPQEI
                                       98      125   GMGQGKIGYTTGAQPAPRNSERQGWAID
                                       154     165   AGVANPAGNTDC
                                       173     182   EDVTNPNSCV

###### 

**Selected High-Affinity Binding (IC50 \< 50 nM) Nine-mer Mouse MHC Class I Epitopes**

  Serial No.   Allergen    GI number   Start   End   Epitope
  ------------ ----------- ----------- ------- ----- -----------
  **1**        *Asp f1*    166486      2       10    VAIKNLFLL
                                       148     156   VIYTYPNKV
                                       87      95    KLIKGRTPI
  **2**        *Asp f2*    1881574     102     110   MEAVGAYDV
  **3**        *Asp f4*    3005839     8       16    YATINGVLV
                                       162     170   LEAGETKYV
  **4**        *Asp f5*    3776613                    
  **5**        *Asp f7*    2879888     41      49    SENVVALPV
  **6**        *Asp f9*    2879890     244     252   TMYVKSVRI
                                       167     175   QETFHTYTI
  **7**        *Asp f15*   3005841     25      33    NEARDAIPV
                                       5       13    TPISLISLF
  **8**        *Asp f16*   3643813     157     165   QETFHTYTI
  **9**        *Asp f17*   2980819     6       14    REAPAVGVI
                                       82      90    VEGVIDDLI
  **10**       *Asp f34*   133920236   67      75    DEKSATFYI

MHC, major histocompatibilty complex.

Furthermore, T cells and MHC-I and MHC-II class epitopes have been predicted by the ANN method.^[@B18]^ We considered a low IC50 value for epitope prediction. On the basis of IC50 value, epitopes were classified into three categories: high-affinity (IC50 \< 50 nM), intermediate (IC50 \< 500), and low-affinity (IC50\<) binding epitopes. Two allergenic proteins, *Asp f5* and *Asp f7*, did not contain any high-affinity binding MHC class I T cell epitopes for mouse and human, respectively. We use all mouse MHC class I alleles and eight human alleles (A\*0101, A\*0201, A\*2402, A\*0301, A\*1101, B\*0702, B\*0801, and B\*1501) that cover 90% of the world population^[@B39]^ ([Tables 3--6](#T3 T4 T5 T6){ref-type="table"}). Furthermore, four allergenic proteins, *Asp f1*, *Asp f2*, *Asp f4*, and *Asp f5*, were predicted to have high-affinity binding mouse MHC class II-restricted epitopes, whereas all 10 allergenic proteins showed high-affinity human MHC class II-restricted T cell epitopes. The fifteen-mer MHC class II-restricted T cell epitopes are presented in [Tables 6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}. Previously, Chaudhary et al. tested the therapeutic potential of *Asp f1* allergen epitopes (INQQLNPKTNKWEDK, INQQLNPK, LNPKTNKWEDK) in sensitized BALB/c mice. They observed the increase in production of Th1 cytokines and suppression of lung eosinophilia by *Asp f1* peptides. Thus, they establish the use of allergen peptides to control allergenic reactions in mice and open the way for human study.^[@B27]^ Our analysis also predicted the same B cell and T cell (MHC-II class) epitopic peptides that are used by Chaudhary et al. and suggested a strong correlation between *in silico* prediction and experimental evidences. We further analyze the epitopic data to screen common epitopic peptides for mouse and human so that they can be tested first on mouse model of *A. fumigatus*-induced allergy or infection model, and then the promising results from these studies can go for clinical trials for human use. Three allergenic proteins, *Asp f1*, *Asp f2*, and *Asp f5*, contained overlapping mouse and human MHC class I and II epitopes ([Table 7](#T7){ref-type="table"}), whereas only two allergic proteins, *Asp f17* and *Asp f34*, contained overlapping human MHC class I and II epitopes ([Table 8](#T8){ref-type="table"}). It has been suggested that the cell wall proteins of *A. fumigatus* having no homology with humans, but showing homology with other fungal proteins, can be considered as ideal vaccine candidates against fungal pathogens.^[@B40]^ Recently, Tiwari et al. found the *Asp fl 2* allergenic protein at germinating stage of *Aspergillus flavus* and showed no homology with human proteome.^[@B41]^ Previously, Gautam et al. have also reported *Asp f2* and *Asp f13* using the immunoproteomic approach and showed antibodies against these proteins in the serum samples of ABPA patients.^[@B42]^ Furthermore, Virginio et al. identified *Asp f 12* and *Asp f 22* from cell wall extracts of A. *fumigatus\'s* germinating conidia and also confirmed the presence of antibodies in patient serum samples against *Asp f 12* and *Asp f 22*.^[@B43]^ Thus, the epitopic regions (predicted in our study) from these allergens may also be considered as promising vaccine candidates that potentially block the germinating conidia in the host. Furthermore, overlapping epitopes (MHC class I and II) were also recognized as B cell epitopes. So, these identified epitopes might be involved in both humoral and cell-mediated immunity (CD4^+^ and CD8^+^), which will be suitable for experimental studies in combination or alone in a mouse model of *A. fumigatus*-induced infection or for *in vitro* studies in human cell lines ([Table 9](#T9){ref-type="table"}). Previously, various studies showed the immunodominant role of allergens as vaccine or allergy shot candidates.^[@B7],[@B44]^ Furthermore, allergen SIT or allergen shots balance the immune response, specially T~H~1 and T~H~2 immune response, and control the undesirable immune reactions.^[@B27],[@B45]^

###### 

**Selected High-Affinity Binding (IC50 \< 50 nM) Nine-mer Human MHC Class I Epitopes**

  Serial No.   Allergen    GI number   Start   End   Epitope
  ------------ ----------- ----------- ------- ----- -----------
  **1**        *Asp f1*    166486      118     126   HYLLEFPTF
                                       9       17    LLAATAVSV
                                       147     155   RVIYTYPNK
  **2**        *Asp f2*    1881574     9       17    VLLPLAAPL
                                       181     189   ASDLMHRLY
                                       198     206   WVDHFADGY
                                       15      23    APLVATLPT
                                       163     171   SMCSQGYTV
                                       94      102   KYFGNRPTM
                                       183     191   DLMHRLYHV
  **3**        *Asp f4*    3005839     244     252   SIISHGLSK
                                       272     280   VPGPTRLVV
                                       31      39    APVSQATPV
                                       244     252   SIISHGLSK
                                       91      99    PSGSGIFYK
  **4**        *Asp f5*    3776613     529     537   MLYEVLWNL
                                       242     250   YVAEADYQV
                                       312     320   RPSSSSLSF
                                       76      84    KMIAPDATF
                                       334     342   YIDASIIQL
                                       19      27    HPAHQSYGL
                                       495     503   RQYPYSTSL
                                       125     133   KVFSYGNSF
                                       4       12    LLLAGALAL
                                       316     324   SSLSFKYPY
                                       314     322   SSSSLSFKY
                                       348     356   IYHDLLYTL
  **5**        *Asp f7*    2879888                    
  **6**        *Asp f9*    2879890     235     243   LTDYSAGPY
                                       15      23    YTAAALAAV
                                       47      55    GLAASTYTA
                                       192     200   RTLTYNDAK
                                       171     179   HTYTIDWTK
                                       141     149   QVQTNYFGK
                                       95      103   TDFYFFFGK
                                       5       13    ILRSADMYF
                                       7       15    RSADMYFKY
  **7**        *Asp f15*   3005841     96      104   LQYEQNTIY
  **8**        *Asp f16*   3643813     251     259   HLLGQLWLL
                                       381     389   ALWCSAPSL
                                       5       13    YTAAALAAV
                                       285     293   SSASSTSSK
                                       198     206   TPMRLRLAA
                                       182     190   RTLTYNDAK
                                       161     169   HTYTIDWTK
                                       333     341   SSNTGSWLR
                                       242     250   RERQPRRVL
                                       131     139   QVQTNYFGK
                                       245     253   QPRRVLHLL
                                       85      93    TDFYFFFGK
                                       19      206   TPMRLRLAA
                                       285     293   SSASSTSSK
                                       417     425   FGIGVSPSF
  **9**        *Asp f17*   2980819     84      92    GVIDDLISK
                                       23      31    ALASAVSSY
                                       130     138   SLSDIAAQL
                                       118     126   SLAKAISAK
                                       113     121   YTAADSLAK
                                       98      106   AANAGGTVY
                                       85      93    VIDDLISKK
                                       118     126   SLAKAISAK
  **10**       *Asp f34*   133920236   74      82    YIQDGSLYL
                                       175     183   VTNPNSCVY
                                       175     183   VTNPNSCVY
                                       45      53    FSAAKSSIF
                                       65      73    RPDEKSATF
                                       61      69    ASCDRPDEK

###### 

**Selected High-Affinity Binding (IC50 \< 50 nM) Fifteen-mer Mouse MHC Class II Epitopes**

  Serial No.   Allergen    GI number   Start   End   Epitope
  ------------ ----------- ----------- ------- ----- ------------------
  **1**        *Asp f1*    166486      9       23    LLAATAVSVLAAPSP
                                       8       22    FLLAATAVSVLAAPS
  **2**        *Asp f2*    1881574     5       19    LRLAVLLPLAAPLVA
  **3**        *Asp f4*    3005839     39      53    VSNAVAAAAAASTPE
                                       38      52    PVSNAVAAAAAASTP
  **4**        *Asp f5*    3776613     318     332   LSFKYPYSVSSSPPS
                                       319     333   SFKYPYSVSSSPPSS
  **5**        *Asp f17*   2980819     93      108   KDKFVAANAGGTVYED
  **6**        *Asp f34*   133920236   75      89    IQDGSLYLYAASATP

###### 

**Selected High-Affinity Binding (IC50 \< 50 nM) Fifteen-mer Human MHC Class II Epitopes**

  Serial No.   Allergen    GI number   Start   End   Epitope
  ------------ ----------- ----------- ------- ----- -----------------
  **1**        *Asp f1*    166486      1       15    MVAIKNLFLLAATAV
                                       39      53    PKTNKWEDKRLLYSQ
                                       40      54    KTNKWEDKRLLYSQA
                                       49      63    LYSQAKAESNSHHAP
                                       75      89    HWFTNGYDGNGKLIK
  **2**        *Asp f2*    1881574     4       18    LLRLAVLLPLAAPLV
                                       226     240   AFEYFALEAYAFDIA
                                       15      29    APLVATLPTSPVPIA
                                       204     218   DGYDEVIALAKSNGT
  **3**        *Asp f4*    3005839     5       20    DTVYATINGVLVSWI
                                       37      51    TPVSNAVAAAAAAST
                                       40      54    GELCSIISHGLSKVI
  **4**        *Asp f5*    3776613     1       15    MRGLLLAGALALPAS
                                       179     193   EKESYVFKGVSGTVS
                                       64      78    PQSYVEVATQHVKMI
                                       576     590   CNPNFVQARDAILDA
                                       505     519   TNPLTYTSVNSLNAV
                                       308     322   LNNYRPSSSSLSFKY
                                       305     319   PSYLNNYRPSSSSLS
  **5**        *Asp f7*    2879888     15      28    VGQLTYYDTATSASA
  **6**        *Asp f9*    2879890     9       23    ADMYFKYTAAALAAV
                                       18      32    AALAAVLPLCSAQTW
                                       238     252   YSAGPYTMYVKSVRI
                                       274     288   KFDGSVDISSSSSVT
                                       104     118   AEVVMKAAPGTGVVS
  **7**        *Asp f15*   3005841     68      82    GSVPGFARIGGAPTI
                                       6       20    PISLISLFVSSALAA
                                       1       15    MKFTTPISLISLFVS
  **8**        *Asp f16*   3643813     102     116   GGTVYEDLKAQYTAA
                                       43      57    SEKLVSTINSGVDTV
                                       100     114   NAGGTVYEDLKAQYT
                                       114     128   TAADSLAKAISAKVP
                                       15      29    SDISAQTSALASAVS
  **9**        *Asp f17*   2980819     1       15    MYFKYTAAALAAVLP
                                       260     274   AEHQVRRLRRYSSSS
                                       196     210   PQTPMRLRLAAGPAA
                                       93      108   AEVVMKAAPGTGVVS
                                       340     354   LRLRLWLWLYSSTGS
  **10**       *Asp f34*   133920236   1       15    MQIKSFVLAASAAAT
                                       39      53    AVQYQPFSAAKSSIF
                                       48      62    AKSSIFAGLNSQNAS
                                       75      89    IQDGSLYLYAASATP
                                       25      39    TNKYFGIVAIHSGSA

###### 

**Common or Overlapping Epitopes of Allergens Recognizing MHC Class I and MHC Class II Alleles of Human and Mouse**

  S. No.   Allergen    Mouse MHC class I      Mouse MHC class II           Human MHC class I      Human MHC class II
  -------- ----------- ---------------------- ---------------------------- ---------------------- ----------------------------
  **1**    *Asp f1*    148--156 (VIYTYPNKV)                                147--155 (RVIYTYPNK)    
                                              9--23 (LLAATAVSVLAAPSP)      9--17 (LLAATAVSV)      1--15 (MVAIKNLFLLAATAV)
  **2**    *Asp f2*                           5--19 (LRLAVLLPLAAPLVA)      9--17 (VLLPLAAPL)      4--18 (LLRLAVLLPLAAPLV)
  **3**    *Asp f5*                           318--332 (LSFKYPYSVSSSPPS)   316--324 (SSLSFKYPY)   308--322 (LNNYRPSSSSLSFKY)
                                              319--333 (SFKYPYSVSSSPPSS)   314--322 (SSSSLSFKY)   305--319 (PSYLNNYRPSSSSLS)
  **4**    *Asp f17*                          93--108 (DKFVAANAGGTVYED)    98--106 (AANAGGTVY)     
  **5**    *Asp f34*                          75--89 (IQDGSLYLYAASATP)     74--82 (YIQDGSLYL)      

###### 

**Potential Antigenic Allergen Proteins for Vaccine Candidate**

  Serial No.   Allergen    GI Number   GenBank protein ID   Protein name             Immune response
  ------------ ----------- ----------- -------------------- ------------------------ ----------------------
  1            *Asp f1*    166486      AAB07779             Mitogillin               Cellular and humoral
  2            *Asp f2*    1881574     AAC69357             Hypothetical protein     Cellular and humoral
  3            *Asp f5*    3776613     CAA83015             Metalloprotease          Cellular and humoral
  4            *Asp f17*   2980819     CAA12162             IgE-binding protein      Cellular and humoral
  5            *Asp f34*   133920236   CAM54066             cell wall protein PhiA   Cellular and humoral

Modeling of tertiary structure {#s015}
------------------------------

These five allergenic proteins that have overlapping MHC class I and MHC class II T cell epitopes were used to predict 3D modeled structure. Previously, *Asp f1*, *Asp f2*, *Asp f3*, and *Asp f16* recombinant allergens have been tested as vaccine candidates.^[@B7],[@B9],[@B46]^ Of five promising allergens as vaccine or allergen shot candidates, Phyre2 server predicted 3D structure template for *Asp f1* and *Asp f5* only ([Figs. 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). It identified multiple templates based on the best aligned sequence for some of the proteins. The best structural template was selected for *Asp f1* and *Asp f5* manually on the basis of best alignment length, a minimum number of gaps, and higher identity. For *Asp f1* and *Asp f5* structure models, unique template IDs (d1jbsa and c4k90A) were chosen. *Asp f1* allergenic protein predicted to be a member of the ribonuclease family, whereas *Asp f5* predicted to be an extracellular metalloproteinase. Furthermore, predicted model structures were submitted to energy minimization and structure refinement using ModRefiner and YASARA force field energy minimization server. After that modeled structures were validated by RAMPAGE. The Ramachandran plot predicted the structure stability of modeled structure. For *Asp f1*, 95.2% residues were found in the favored region, 4.8% in allowed region, and 0% in outlier region ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}), and in case of *Asp f5*, 88.6% residues were in the favored region, 7.3% residues were in allowed region, and 4.1% residues were in outlier region ([Supplementary Fig. S2](#SD2){ref-type="supplementary-material"}). Furthermore, PyMOL was used to illustrate the spatial locations of residues in some epitopic peptides, which predicted to be located on the surface of the protein and presented at N-terminal of the protein. It is evident that T cell and B cell epitopes are exposed to the surface of the protein and therefore it supports that the predicted sequence may act as a potential vaccine peptide^[@B32]^ ([Figs. 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). A similar method has been used for prediction of the 3D structure of proteins for vaccine candidate.^[@B19]^

![Predicted 3D structure of *Asp f1* and B cell and T cell epitopic regions. **(A)** The B and T cell epitopic region of *Asp f1*, red surface shows MHC-I T cell epitopic region, whereas green surface-exposed region shows overlapped T and B cell epitopes. **(B)** 3D structure of *Asp f1.* MHC, major histocompatibility complex.](fig-2){#f2}

![Predicted 3D structure of *Asp f5* and B cell and T cell epitopic regions. **(A)** The B and T cell epitopic region of *Asp f5*, red surface shows MHC-I and II T cell epitopic region, whereas green surface-exposed region shows overlapped T and B cell epitopes. **(B)** 3D structure of *Asp f5.*](fig-3){#f3}

Thus, the vaccination, alone and combination of selected peptides from these five allergenic proteins, can be used to combat Aspergillus-induced infection due to activation of both humoral and cell-mediated immune responses. On the other side, small T cell peptides (8--9 mer) ([Table 10](#T10){ref-type="table"}) can be used as allergen shot candidates because IgE antibody recognizes large epitopic peptides (B cell epitopes), thus these small peptides can activate T cell immune response and eliminate IgE activation.^[@B47]^

###### 

**Potential Allergen Shot Peptides of Selected Allergenic Proteins**

  Serial No.   Allergen    GI Number   T cell peptides
  ------------ ----------- ----------- -----------------
  1            *Asp f1*    166486      HYLLEFPTF
                                       VIYTYPNKV
                                       KLIKGRTPI
  2            *Asp f2*    1881574     MEAVGAYDV
  3            *Asp f17*   2980819     REAPAVGVI
                                       VEGVIDDLI
  4            *Asp f34*   133920236   DEKSATFYI

Conclusion {#s016}
==========

A total of five potential allergenic proteins (*Asp f1*, *Asp f2*, *Asp f5*, *Asp f17*, and *Asp f34*) from *A. fumigatus* as vaccine or allergy shot candidates were obtained. Epitopic peptides from these five proteins in combination or alone could be used to prioritize in experimental validation with human cell lines or in mouse model of *A. fumigatus* infection or allergic mouse models. Previously, Chaudhary et al. showed the therapeutic use of *Asp f1* allergen epitopes (INQQLNPKTNKWEDK, INQQLNPK, LNPKTNKWEDK) in sensitized BALB/c mice. Chaudhary et al. observed increase in production of Th1 cytokines and suppression of lung eosinophilia by *Asp f1* peptides. Thus, they established the use of allergen peptides to control allergenic reaction in mice. In addition, Gautam et al. identified *Asp f2* using the immunoproteomic approach in ABPA patients, which correlates with our *in silico* results. Furthermore, we also analyzed the 3D structure of *Asp f1* and *Asp f5* allergenic proteins. Overall, resulting peptides from our analysis could be subjected to experimental prioritization to explore vaccine candidates or allergy immunotherapy against *Aspergillus*-mediated infections.
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